---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-23-000800"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:04:33.051769+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lexaria Bioscience prices public offering of 2.1M units at $0.95/unit for $2.0M gross proceeds

## Summary
- 2,106,000 units priced at $0.95 each, each unit comprising one share of common stock and one warrant.
- Gross proceeds expected ~$2.0M before fees; warrants exercisable at $0.95 for 5 years.
- Offering expected to close May 11, 2023; Maxim Group LLC sole placement agent.
- Registration statement on Form S-1 (File No. 333-271096) declared effective May 8, 2023.

## SEC filing metadata
- accession: 0001640334-23-000800
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000800/0001640334-23-000800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000800/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-23-000800
- JSON: https://secwatch.observer/filing/0001640334-23-000800.json
- Plain text: https://secwatch.observer/filing/0001640334-23-000800.txt

## Key facts
- Material Agreements
  Lexaria Bioscience Corp. entered into Placement Agency Agreement with Maxim Group LLC (effective 2023-05-08).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Maxim Group LLC
  - Effective: 2023-05-08
  source text: On May 8, 2023, Lexaria Bioscience Corp. (the “Company”) entered into a placement agency agreement dated as of May 8, 2023 (the “PAA”) with Maxim Group LLC (the “Placement Agent”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000800/0001640334-23-000800-index.htm
- Material Agreements
  Lexaria Bioscience Corp. entered into Security Purchase Agreement with certain institutional investors valued at up to an aggregate of $247,000 of Units (effective 2023-05-08).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: up to an aggregate of $247,000 of Units
  - Effective: 2023-05-08
  source text: On May 8, 2023, the Company also entered into a security purchase agreement (the “Purchase Agreement”) with certain institutional investors named therein (the “Purchasers”) in connection with the Offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000800/0001640334-23-000800-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.